Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
IPCA LABS | AUROBINDO PHARMA | IPCA LABS/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 22.4 | 9.9 | 227.3% | View Chart |
P/BV | x | 4.3 | 1.8 | 235.6% | View Chart |
Dividend Yield | % | 0.3 | 0.6 | 48.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IPCA LABS Mar-19 |
AUROBINDO PHARMA Mar-19 |
IPCA LABS/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,042 | 830 | 125.5% | |
Low | Rs | 590 | 527 | 112.0% | |
Sales per share (Unadj.) | Rs | 298.6 | 333.9 | 89.4% | |
Earnings per share (Unadj.) | Rs | 35.0 | 40.4 | 86.7% | |
Cash flow per share (Unadj.) | Rs | 49.4 | 51.8 | 95.5% | |
Dividends per share (Unadj.) | Rs | 3.00 | 2.50 | 120.0% | |
Dividend yield (eoy) | % | 0.4 | 0.4 | 99.8% | |
Book value per share (Unadj.) | Rs | 247.1 | 237.1 | 104.2% | |
Shares outstanding (eoy) | m | 126.35 | 585.91 | 21.6% | |
Bonus/Rights/Conversions | ESOS | ESOP | - | ||
Price / Sales ratio | x | 2.7 | 2.0 | 134.5% | |
Avg P/E ratio | x | 23.3 | 16.8 | 138.7% | |
P/CF ratio (eoy) | x | 16.5 | 13.1 | 125.9% | |
Price / Book Value ratio | x | 3.3 | 2.9 | 115.4% | |
Dividend payout | % | 8.6 | 6.2 | 138.4% | |
Avg Mkt Cap | Rs m | 103,108 | 397,569 | 25.9% | |
No. of employees | `000 | 13.4 | 17.9 | 75.3% | |
Total wages/salary | Rs m | 7,874 | 25,849 | 30.5% | |
Avg. sales/employee | Rs Th | 2,807.0 | 10,956.9 | 25.6% | |
Avg. wages/employee | Rs Th | 585.8 | 1,447.7 | 40.5% | |
Avg. net profit/employee | Rs Th | 329.0 | 1,324.3 | 24.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 37,732 | 195,636 | 19.3% | |
Other income | Rs m | 577 | 1,553 | 37.1% | |
Total revenues | Rs m | 38,309 | 197,189 | 19.4% | |
Gross profit | Rs m | 6,901 | 39,519 | 17.5% | |
Depreciation | Rs m | 1,824 | 6,680 | 27.3% | |
Interest | Rs m | 189 | 2,626 | 7.2% | |
Profit before tax | Rs m | 5,465 | 31,767 | 17.2% | |
Minority Interest | Rs m | 0 | 27 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
Tax | Rs m | 1,042 | 7,269 | 14.3% | |
Profit after tax | Rs m | 4,422 | 23,645 | 18.7% | |
Gross profit margin | % | 18.3 | 20.2 | 90.5% | |
Effective tax rate | % | 19.1 | 22.9 | 83.4% | |
Net profit margin | % | 11.7 | 12.1 | 97.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 23,778 | 153,645 | 15.5% | |
Current liabilities | Rs m | 10,975 | 120,429 | 9.1% | |
Net working cap to sales | % | 33.9 | 17.0 | 199.8% | |
Current ratio | x | 2.2 | 1.3 | 169.8% | |
Inventory Days | Days | 104 | 135 | 76.7% | |
Debtors Days | Days | 66 | 64 | 103.5% | |
Net fixed assets | Rs m | 20,368 | 103,909 | 19.6% | |
Share capital | Rs m | 253 | 586 | 43.1% | |
"Free" reserves | Rs m | 30,971 | 138,322 | 22.4% | |
Net worth | Rs m | 31,224 | 138,908 | 22.5% | |
Long term debt | Rs m | 1,409 | 1,800 | 78.3% | |
Total assets | Rs m | 45,507 | 264,544 | 17.2% | |
Interest coverage | x | 30.0 | 13.1 | 228.7% | |
Debt to equity ratio | x | 0 | 0 | 348.2% | |
Sales to assets ratio | x | 0.8 | 0.7 | 112.1% | |
Return on assets | % | 10.1 | 9.9 | 102.0% | |
Return on equity | % | 14.2 | 17.0 | 83.2% | |
Return on capital | % | 17.3 | 23.8 | 72.7% | |
Exports to sales | % | 45.9 | 0 | - | |
Imports to sales | % | 16.6 | 0 | - | |
Exports (fob) | Rs m | 17,308 | NA | - | |
Imports (cif) | Rs m | 6,266 | NA | - | |
Fx inflow | Rs m | 17,308 | 97,316 | 17.8% | |
Fx outflow | Rs m | 6,266 | 40,589 | 15.4% | |
Net fx | Rs m | 11,042 | 56,727 | 19.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,923 | 16,220 | 30.3% | |
From Investments | Rs m | -1,563 | -28,768 | 5.4% | |
From Financial Activity | Rs m | -1,832 | 19,191 | -9.5% | |
Net Cashflow | Rs m | 1,528 | 6,656 | 23.0% |
Indian Promoters | % | 45.9 | 54.1 | 84.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 11.4 | 8.0 | 143.4% | |
FIIs | % | 25.3 | 27.7 | 91.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.4 | 10.2 | 170.6% | |
Shareholders | 36,892 | 69,601 | 53.0% | ||
Pledged promoter(s) holding | % | 2.1 | 8.6 | 25.0% |
Compare IPCA LABS With: PIRAMAL ENTERPRISES GSK PHARMA DR. DATSONS LABS DR. REDDYS LAB NOVARTIS
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
Indian share markets fell sharply during closing hours today and ended deep in the red. The BSE Sensex stood lower by 248 points, while the NSE Nifty closed down by 81 points.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
What we can learn from one of the greatest traders to have ever lived.
Should you invest in growth stocks or value stocks to make strong returns in this market?
Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.
More